Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Todd Neale

April 03, 2022

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Michael O'Riordan

June 13, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Conference News EAS 2016

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Yael L. Maxwell

June 08, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

Advertisement

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content